Otitis media- Pipeline Insight, 2024

Otitis media- Pipeline Insight, 2024

DelveInsight’s, “Otitis-media- Pipeline Insight, 2024” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Otitis-media pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Otitis-media: Understanding

Otitis-media: Overview

Otitis media is inflammation or infection located in the middle ear. Otitis media can occur as a result of a cold, sore throat, or respiratory infection. Middle ear infections are usually a result of a malfunction of the eustachian tube, a canal that links the middle ear with the throat area. The eustachian tube helps to equalize the pressure between the outer ear and the middle ear. When this tube is not working properly, it prevents normal drainage of fluid from the middle ear, causing a buildup of fluid behind the eardrum. When this fluid cannot drain, it allows for the growth of bacteria and viruses in the ear that can lead to acute otitis media. Different types of otitis media include the following: Acute otitis media. This middle ear infection occurs abruptly causing swelling and redness. Fluid and mucus become trapped inside the ear, causing the child to have a fever and ear pain. Otitis media with effusion. Fluid (effusion) and mucus continue to accumulate in the middle ear after an initial infection subsides. The child may experience a feeling of fullness in the ear and it may affect his or her hearing or may have no symptoms. Chronic otitis media with effusion. Fluid remains in the middle ear for a prolonged period or returns again and again, even though there is no infection. May result in difficulty fighting new infection and may affect the child's hearing. The following are the most common symptoms of otitis media. However, each child may experience symptoms differently. Symptoms may include: Unusual irritability, difficulty sleeping or staying asleep, tugging or pulling at one or both ears, fever, especially in infants and younger children, fluid draining from ear(s), loss of balance, hearing difficulties and ear pain. In addition to a complete medical history and physical examination, child's health care provider will inspect the outer ear(s) and eardrum(s) using an otoscope. Tympanometry is a test that can be performed in most health care providers' offices to help determine how the middle ear is functioning. It does not tell if the child is hearing or not, but helps to detect any changes in pressure in the middle ear. This is a difficult test to perform in younger children because the child needs to remain still and not cry, talk, or move. Treatment will depend on the type of otitis media.

""Otitis-media- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Otitis-media pipeline landscape is provided which includes the disease overview and Otitis-media treatment guidelines. The assessment part of the report embraces, in depth Otitis-media commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Otitis-media collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Otitis-media R&D. The therapies under development are focused on novel approaches to treat/improve Otitis-media.

Otitis-media Emerging Drugs Chapters

This segment of the Otitis-media report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Otitis-media Emerging Drugs

• V 114: Merck & Co

V114 consists of pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein and includes serotypes 22F and 33F, which are commonly associated with invasive pneumococcal disease worldwide and are not contained in the pneumococcal conjugate vaccine currently licensed for use in adults. Currently, the drug is in Phase III stage of Clinical Trial evaluation for the treatment of Acute Otitis Media (AOM).

• CMTX-301: Clarametyx Biosciences

CMTX-301 employs Clarametyx’ anti-DNABII technology through a vaccination approach in at-risk populations. This approach prevents the development of bacterial biofilm, enabling the body’s normal immune responses to more effectively destroy bacterial pathogens. The first targeted indication is otitis media (OM).Preventing formation of biofilm and eliminating bacteria at potential infection sites will reduce the incidence of OM, and thus reduce antibiotic usage.Currently, the drug is in Preclinical stage of development for the treatment of otitis media (OM).

• VAX-24: Vaxcyte

VAX-24, is an investigational drug being developed by Vaxcyte for the treatment of otitis media (OM). Vaxcyte aims to efficiently create and deliver high-fidelity, broad-spectrum vaccines, such as VAX-24, by using modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform. Vaxcyte is deploying this approach with VAX-24 in order to add more pneumococcal strains without compromising the overall immune response.

Further product details are provided in the report……..

Otitis-media: Therapeutic Assessment

This segment of the report provides insights about the different Otitis-media drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Otitis-media

There are approx. 7+ key companies which are developing the therapies for Otitis-media. The companies which have their Otitis-media drug candidates in the most advanced stage, i.e. phase III include, Merck & Co

Phases

DelveInsight’s report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Otitis-media pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Otitis-media: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Otitis-media therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Otitis-media drugs.

Otitis-media Report Insights

• Otitis-media Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Otitis-media Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Otitis-media drugs?
• How many Otitis-media drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Otitis-media?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Otitis-media therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Otitis-media and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck & Co
• Clarametyx Biosciences
• Vaxcyte
• CEOLIA Pharma
• NanoCarrier

Key Products

• V 114
• CMTX-301
• VAX-24
• ENT 103
• VAX-XP